WHO ICTRP trial

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group…

NL-OMON41832 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting

Key facts

Trial ID NL-OMON41832
Public title A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS)
Scientific title A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS) - TEVA TV5600-CNS-20006…
Primary sponsor TEVA Pharma
Registry Overview of Medical Research in the Netherlands (NL-OMON)
Recruitment status Not Recruiting
Study type Interventional
Phase 2
Countries The Netherlands
Conditions MS Primary Progressive Multiple Sclerosis (PPMS);10012303;Primary Progressive Multiple Sclerosis (PPMS)
Interventions * 0.6 mg arm: 1 capsule containing 0.6 mg laquinimod and the other 2 containing placebo, to be administered orally once daily. * 1.5 mg arm: 3 capsules containing 0.5 mg laquinimod to be administered orally once daily. * Placebo arm: 3…
Registration date May 21, 2015
Target size 26
Secondary IDs 2014-001579-30;NCT02284568;NL50594.029.14
Registry page onderzoekmetmensen.nl

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations